Advertisement

World Journal of Urology

, Volume 37, Issue 10, pp 2199–2205 | Cite as

Liquid chromatography–mass spectrometry identification of serum biomarkers for nocturia in aged men

  • Satoru KiraEmail author
  • Takahiko Mitsui
  • Tatsuya Miyamoto
  • Tatsuya Ihara
  • Hiroshi Nakagomi
  • Yuka Hashimoto
  • Hajime Takamatsu
  • Masayuki Tanahashi
  • Masahiro Takeda
  • Norifumi Sawada
  • Karl-Erik Andersson
  • Masayuki Takeda
Original Article

Abstract

Purpose

We aimed to investigate the association between nocturia and serum metabolites identified using metabolomics analysis.

Methods

This study enrolled 66 men aged 65–80 years, recruited from the outpatient department of a university hospital. The participants were stratified as follows: Nocturia group [45 men with any total international prostate symptom score (IPSS) and an average of 3 nights ≥ 1.5 micturitions/night] and Control group (21 men with total IPSS < 8 and an average of 3 nights < 1.5 micturitions/night). The 24-h frequency–volume chart, IPSS, and Quality-of-Life questionnaire were used to evaluate micturition behavior. Serum metabolite profiles were obtained using liquid chromatography–mass spectrometry (LC–MS)-based metabolomics analysis and compared between the two groups using the unpaired t test. The relationship between serum metabolites and nocturia was determined using multivariable logistic regression analysis.

Results

There were no differences in background factors between the Nocturia and Control groups. In the IPSS, mean total scores in the Nocturia and Control groups were 12.4 and 4.0, respectively. On frequency–volume chart analysis, nocturnal urine volume and micturition frequency during daytime and nighttime were significantly higher in the Nocturia group. LC–MS highlighted 13 serum metabolites as potential biomarkers of nocturia. On multivariate analysis, increased levels of palmitoylethanolamide, 4-hydroxydocosahexaenoic acid, 9-hydroxyoctadecadienoic acid, 20-hydroxydocosahexaenoic acid, 13-hydroxyoctadecadienoic acid, arachidonoylethanolamide, eicosapentaenoic acid, 12-hydroxy-eicosatetraenoic acid, and arachidonic acid were associated with nocturia.

Conclusions

In aged men, the pathogenesis of nocturia involves abnormal metabolism in several signaling pathways involving omega-3 and omega-6 polyunsaturated fatty acids, as well as endocannabinoids.

Keywords

Nocturia Aged Liquid chromatography mass spectrometry Metabolomics 

Notes

Acknowledgements

This study was funded by Astellas Pharma, Inc. and designed by Astellas Pharma, Inc. in collaboration with the authors. We thank Ms. Sachiko Tsuchiya for her assistance with data management.

Author contribution

SK: data collection, data analysis, and manuscript writing. TM: data analysis and manuscript editing. TM: data collection and data analysis. TI: data analysis. HN: data collection and data analysis. YH: data analysis. HT: data analysis. MT: data analysis. MT: data analysis and other (supervision). NS: data analysis. K-EA: manuscript editing and other (supervision). MT: data analysis, manuscript editing, and other (supervision)

Funding

This study was funded by Astellas Pharma, Inc.

Compliance with ethical standards

Conflict of interest

The study was designed by Astellas Pharma, Inc. in collaboration with the authors. Several of the authors are employees of Astellas Pharma, Inc. The other authors have no potential competing interests to declare.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Van Kerrebroeck P, Andersson KE (2014) Terminology, epidemiology, etiology, and pathophysiology of nocturia. Neurourol Urodyn 33(S1):S2–S5.  https://doi.org/10.1002/nau.22595 CrossRefPubMedGoogle Scholar
  2. 2.
    Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, Mollon P, Tamimi N, Rosen RC, McKinlay JB (2009) Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol 182(2):616–624.  https://doi.org/10.1016/j.juro.2012.11.026 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Fitzgerald MP, Litman HJ, Link CL, McKinlay JB, BACH Survey Investigators (2007) The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey. J Urol 177(4):1385–1389.  https://doi.org/10.1016/j.juro.2006.11.057 CrossRefPubMedGoogle Scholar
  4. 4.
    Fine ND, Weiss JP, Wein AJ (2017) Nocturia: consequences, classification, and management. F1000Res 6:1627.  https://doi.org/10.12688/f1000research.11979.1 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Yoshimi N, Futamura T, Kakumoto K, Salehi AM, Sellgren CM, Holmén-Larsson J, Jakobsson J, Pålsson E, Landén M, Hashimoto K (2016) Blood metabolomics analysis identifies abnormalities in the citric acid cycle, urea cycle, and amino acid metabolism in bipolar disorder. BBA Clin 5:151–158.  https://doi.org/10.1016/j.bbacli.2016.03.008 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    White L, Ma J, Liang S, Sanchez-Espiridion B, Liang D (2017) LC–MS/MS determination of d-mannose in human serum as a potential cancer biomarker. J Pharm Biomed Anal 137:54–59.  https://doi.org/10.1016/j.jpba.2016.12.017 CrossRefPubMedGoogle Scholar
  7. 7.
    Liu Y, Qing H, Deng Y (2014) Biomarkers in Alzheimer’s disease analysis by mass spectrometry-based proteomics. Int J Mol Sci 15(5):7865–7882.  https://doi.org/10.3390/ijms15057865 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Tessitore A, Gaggiano A, Cicciarelli G, Verzella D, Capece D, Fischietti M, Zazzeroni F, Alesse E (2013) Serum biomarkers identification by mass spectrometry in high-mortality tumors. Int J Proteom 2013:125858.  https://doi.org/10.1155/2013/125858 CrossRefGoogle Scholar
  9. 9.
    Weiss JP, Blaivas JG, Blanker MH, Bliwise DL, Dmochowski RR, Drake M, DuBeau CE, Hijaz A, Rosen RC, Van Kerrebroeck PE, Wein AJ (2013) The New England Research Institutes, Inc. (NERI) Nocturia advisory conference 2012: focus on outcomes of therapy. BJU Int 111(5):700–716.  https://doi.org/10.1111/j.1464-410X.2012 CrossRefPubMedGoogle Scholar
  10. 10.
    Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS (2008) The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol 54(6):1379–1384.  https://doi.org/10.1016/j.eururo.2007.11.026 CrossRefPubMedGoogle Scholar
  11. 11.
    Addla SK, Adeyoju AB, Neilson D, O’Reilly P (2006) Diclofenac for treatment of nocturia caused by nocturnal polyuria: a prospective, randomised, double-blind, placebo-controlled crossover study. Eur Urol 49(4):720–725.  https://doi.org/10.1016/j.eururo.2005.11.026 CrossRefPubMedGoogle Scholar
  12. 12.
    Falahatkar S, Mokhtari G, Pourreza F, Asgari SA, Kamran AN (2008) Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 72(4):813–816.  https://doi.org/10.1016/j.urology.2008.04.069 CrossRefPubMedGoogle Scholar
  13. 13.
    Aoki Y, Yokoyama O (2012) Metabolic syndrome and nocturia. Low Urin Tract Symptoms 4(S1):11–15.  https://doi.org/10.1111/j.1757-5672.2011.00118.x CrossRefPubMedGoogle Scholar
  14. 14.
    Waddington EI, Croft KD, Sienuarine K, Latham B, Puddey IB (2003) Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis 167(1):111–120.  https://doi.org/10.1016/S0021-9150(02)00391-X CrossRefPubMedGoogle Scholar
  15. 15.
    Ku G, Thomas CE, Akeson AL, Jackson RL (1992) Induction of interleukin 1 beta expression from human peripheral blood monocyte-derived macrophages by 9-hydroxyoctadecadienoic acid. J Biol Chem 267(20):14183–14188PubMedGoogle Scholar
  16. 16.
    Tsujimura A, Hiramatsu I, Aoki Y, Shimoyama H, Mizuno T, Nozaki T, Shirai M, Kobayashi K, Kumamoto Y, Horie S (2017) Atherosclerosis is associated with erectile function and lower urinary tract symptoms, especially nocturia, in middle-aged men. Prostate Int 5(2):65–69.  https://doi.org/10.1016/j.prnil.2017.01.006 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Inci M, Sarli B, Davarci M, Yalcinkaya FR, Rifaioğlu MM, Davran R, Arica S, Motor S, Demirbaş O (2013) Relationship between endothelial dysfunction and nocturia with benign prostatic hyperplasia. Scand J Urol 47(5):384–389.  https://doi.org/10.3109/21681805.2012.762038 CrossRefPubMedGoogle Scholar
  18. 18.
    Andersson KE (2016) Potential future pharmacological treatment of bladder dysfunction. Basic Clin Pharmacol Toxicol 119(S3):75–85.  https://doi.org/10.1111/bcpt.12577 CrossRefPubMedGoogle Scholar
  19. 19.
    Hedlund P (2014) Cannabinoids and the endocannabinoid system in lower urinary tract function and dysfunction. Neurourol Urodyn 33(1):46–53.  https://doi.org/10.1002/nau.22442 CrossRefPubMedGoogle Scholar
  20. 20.
    Kavia RB, De Ridder D, Constantinescu CS, Stott CG, Fowler CJ (2010) Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 16(11):1349–1359.  https://doi.org/10.1177/1352458510378020 CrossRefPubMedGoogle Scholar
  21. 21.
    Vemuri VK, Janero DR, Makriyannis A (2008) Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome. Physiol Behav 93(4–5):671–686.  https://doi.org/10.1016/j.physbeh.2007.11.012 CrossRefPubMedGoogle Scholar
  22. 22.
    Simopoulos AP (2011) Importance of the omega-6/omega-3 balance in health and disease: evolutionary aspects of diet. World Rev Nutr Diet 102:10–21.  https://doi.org/10.1159/000327785 CrossRefPubMedGoogle Scholar
  23. 23.
    Lauritzen I, Blondeau N, Heurteaux C, Widmann C, Romey G, Lazdunski M (2000) Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 19(8):1784–1793.  https://doi.org/10.1093/emboj/19.8.1784 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Saravanan P, Davidson NC, Schmidt EB, Calder PC (2010) Cardiovascular effects of marine omega-3 fatty acids. Lancet 376(9740):540–550.  https://doi.org/10.1016/S0140-6736(10)60445-X CrossRefPubMedGoogle Scholar
  25. 25.
    Suzuki S, Platz EA, Kawachi I, Willett WC, Giovannucci E (2002) Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75(4):689–697.  https://doi.org/10.1093/ajcn/75.4.689 CrossRefPubMedGoogle Scholar
  26. 26.
    Yap TL, Brown C, Cromwell DA, van der Meulen J, Emberton M (2009) The impact of self-management of lower urinary tract symptoms on frequency–volume chart measures. BJU Int 104(8):1104–1108.  https://doi.org/10.1111/j.1464-410X.2009.08497.x CrossRefPubMedGoogle Scholar
  27. 27.
    Breyer BN, Phelan S, Hogan PE, Rosen RC, Kitabchi AE, Wing RR, Brown JS, Look AHEAD Research Group (2014) Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the look AHEAD trial. J Urol 192(1):144–149.  https://doi.org/10.1016/j.juro.2014.02.036 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Satoru Kira
    • 1
    Email author
  • Takahiko Mitsui
    • 1
  • Tatsuya Miyamoto
    • 1
  • Tatsuya Ihara
    • 1
  • Hiroshi Nakagomi
    • 1
  • Yuka Hashimoto
    • 2
  • Hajime Takamatsu
    • 2
  • Masayuki Tanahashi
    • 2
  • Masahiro Takeda
    • 2
  • Norifumi Sawada
    • 1
  • Karl-Erik Andersson
    • 3
  • Masayuki Takeda
    • 1
  1. 1.Department of Urology, Interdisciplinary Graduate School of Medicine and EngineeringUniversity of YamanashiYamanashiJapan
  2. 2.Pharmacology Research LabsAstellas Pharma IncTsukubaJapan
  3. 3.Institute for Regenerative MedicineWake Forest University School of MedicineWinston-SalemUSA

Personalised recommendations